The CDKN1A antibody is a crucial tool in molecular and cellular biology research, targeting the CDKN1A gene product, p21 (also known as p21WAF1/Cip1). This protein is a cyclin-dependent kinase inhibitor that regulates cell cycle progression by binding to and inhibiting cyclin-CDK complexes, thereby blocking G1/S phase transition. p21 plays a central role in cellular responses to DNA damage, senescence, and apoptosis, acting as a downstream effector of tumor suppressor p53. Dysregulation of p21 is implicated in cancer, aging, and neurodegenerative diseases, making it a key focus in disease mechanism studies.
CDKN1A antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry to detect p21 expression levels and localization. These applications help researchers investigate cell cycle control, DNA damage responses, and therapeutic targets. Antibodies may be monoclonal or polyclonal, with monoclonal variants offering higher specificity and batch consistency. Validation often includes knockout cell line controls or peptide blocking experiments to confirm target specificity.
Commercially available CDKN1A antibodies are offered by major suppliers (e.g., Cell Signaling Technology, Abcam), with species reactivity typically covering human, mouse, and rat samples. Proper antibody selection depends on experimental needs, including compatibility with specific assay formats and post-translational modification detection requirements. Recent studies also explore p21's potential as a biomarker, further driving antibody development for diagnostic applications.